Clinical Trial SuccessTwo patients with CSCC who completed treatment with PH-762 showed a complete response (100% tumor clearance).
Immunotherapy PotentialINTASYL technology enables the creation and precision delivery of uniquely modified small interfering RNA, showing potential for multiple immunotherapeutic applications.
Safety And TolerabilityPH-762 intratumoral (IT) injection has been well-tolerated in all enrolled patients, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects.